






Pipeline

	Indication/Target	Program	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Trial Name / Collaborator	
Late stage	NSCLC (2 nd /3 rd line)	Plinabulin + Docetaxel	▶						DUBLIN-3
	CIN Prevention	Plinabulin + Pegfilgrastim	▶						PROTECTIVE-1 & PROTECTIVE-2
Investigator Initiated Trials	SCLC (2 nd /3 rd line)	Plinabulin + Nivolumab + Ipilimumab	▶						 RUTGERS
	NSCLC (2 nd /3 rd line PD-1 failed)	Plinabulin + Pembrolizumab + Docetaxel	▶						
	ES-SCLC (1 st line)	Plinabulin + Pembrolizumab + Etoposide / Platinum	▶						
	Multiple cancers (PD-1/PD-L1 failed)	Plinabulin + PD-1/PD-L1 + Radiation	▶						THE UNIVERSITY OF TEXAS 
	AHCT (hematopoietic stem cell transplantation) in Multiple myeloma	Plinabulin + Pegfilgrastim	▶						 Memorial Sloan Kettering Cancer Center
Early Stage	Preclinical assets	BPI-002, BPI-003, BPI-004	▶						
SEED	8 Targets in Oncology, Neurodegeneration, Immunology and Antiviral	Targeted Protein Degradation Molecular Glue Platform	▶					